enVVeno Medical Corp
NVNO Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$6.71
KIRA · Stoqly’s AI analyst, in plain words
- enVVeno Medical Corp lost $19.5M in fiscal 2025.
- Free cash flow was −$15.6M in fiscal 2025, — of revenue.
Market cap
$4.5M
P/E
—
Revenue
—
Net income
−$19.5M
Free cash flow
−$15.6M
Operating margin
—
enVVeno Medical Corp in 30 seconds · fiscal 2025
Does it make a profit?
−$19.5M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What enVVeno Medical Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- enVVeno Medical Corp
- CIK
- 0001661053
enVVeno Medical Corp · NVNO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.2M | — | — | — |
| Revenue growth | 413.5% | 747.4% | — | — | — |
| Net interest income | $0.0M | $0.2M | — | — | — |
| Operating margin | −88,910.5% | −15,485.7% | — | — | — |
| Net income | −$16.5M | −$24.7M | −$23.5M | −$21.8M | −$19.5M |
| Net margin | −86,989.5% | −15,322.4% | — | — | — |
| Diluted EPS | −$1.90 | −$2.20 | −$1.91 | −$44.53 | −$33.06 |
| Cash | |||||
| Cash from operations | −$11.8M | −$15.6M | −$18.9M | −$16.8M | −$15.6M |
| Capital expenditure | $0.4M | $0.1M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$12.2M | −$15.7M | −$18.9M | −$16.9M | −$15.6M |
| FCF margin | −64,294.7% | −9,772.7% | — | — | — |
| Share count change | 572.1% | 29.4% | 9.5% | −96.0% | 20.2% |
| Debt and strength | |||||
| Cash and short-term investments | $54.7M | $39.0M | $46.4M | $43.2M | $28.2M |
| Shareholders' equity | $54.4M | $38.7M | $46.2M | $42.2M | $27.1M |
| Current ratio | 34.8x | 25.8x | 34.2x | 20.9x | 13.6x |
| Returns and quality | |||||
| Return on equity | −53.7% | −53.0% | −55.4% | −49.4% | −56.2% |
| Return on tangible equity | −30.4% | −63.7% | −50.9% | −51.8% | −71.8% |
| Piotroski F-score | 3 | 2 | — | — | — |
| Altman Z'' | 16.8 | 7.5 | 13.9 | 7.3 | −6.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
100%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
enVVeno Medical Corp · NVNO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $6.71 a share, the company is worth $4.5M.
Source: SEC EDGAR XBRL filings (CIK 0001661053). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.